1. Clinical & Scientific Overview
Oxytocin, Methylergometrine Maleate & Carboprost (TIP-MED-000249, Reference Code [12.17]) is classified under
Obstetric, Gynaecological & Antifibrinolytic Medicines (Ch 12) as a High-Alert Obstetric Uterotonics (Neurohypophyseal Peptide, Ergot Alkaloid & Prostaglandin F2-alpha).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (Single-Unit Blister Pack Mandate) • ISMP HIGH-ALERT • NLEM 2022.
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.17], p. 163): Oxytocin: Pitocin (Pfizer), Syntocinon (Novartis), Evatocin (Neon — 5 IU/mL); Methylergometrine: Methergin (Novartis — 0.125 mg Tab, 0.2 mg/mL Inj), Utergin; Carboprost: Prostodin (AstraZeneca — 125 mcg/mL, 250 mcg/mL Inj) — Strengths & Forms: Oxytocin Injection (COLD CHAIN 2–8°C): 5 IU/mL, 10 IU/mL (1 mL ampoule). Methylergometrine Tablets: 0.125 mg; Injection: 0.2 mg/mL. Carboprost Tromethamine IM Injection: 125 mcg/mL, 250 mcg/mL.
Oxytocin Injection (COLD CHAIN 2–8°C): 5 IU/mL, 10 IU/mL (1 mL ampoule). Methylergometrine Tablets: 0.125 mg; Injection: 0.2 mg/mL. Carboprost Tromethamine IM Injection: 125 mcg/mL, 250 mcg/mL.
3. Mechanism of Action & Pharmacodynamics
Binds to Gq/11-protein-coupled Oxytocin Receptors (OXTR — whose myometrial density increases 100- to 200-fold during late gestation under oestrogen priming) on uterine smooth muscle cells. Activates Phospholipase C-β, generating IP3 (releasing Ca2+ from sarcoplasmic reticulum) and DAG, which activates Ca2+-Calmodulin/MLCK to increase the frequency and force of rhythmic fundal uterine contractions while stimulating decidual prostaglandin PGF2α synthesis.
4. Therapeutic Indications & Evidence-Supported Uses
- Active Management of the Third Stage of Labour (AMTSL) — WHO/MoHFW drug of choice to prevent and treat Postpartum Haemorrhage (PPH)
- Induction and augmentation of labour in medically indicated term pregnancies
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Prevention of PPH (AMTSL): 10 IU Intramuscularly (IM) immediately after delivery of the anterior shoulder/infant. Treatment of PPH: 10–40 IU in 500–1000 mL Normal Saline/Ringer's Lactate infused IV. Labour Induction: Titrated via infusion pump starting at 1–2 mU/min.
Administration & Meal Timing: Intramuscular (AMTSL) or Titrated Intravenous Infusion via infusion pump (NEVER administer rapid undiluted IV bolus!).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
No dose adjustment required.
Monitor fluid balance during prolonged high-dose infusions (structural similarity to Vasopressin/ADH causes antidiuretic V2 water retention).
No dose adjustment required.
7. Contraindications, Precautions & High-Risk Warnings
- Cephalopelvic disproportion (CPD), transverse lie, placenta praevia, or vasa praevia
- Foetal distress where delivery is not imminent, or prior classical vertical caesarean scar (risk of uterine rupture)
Key Clinical Precautions: No dose adjustment required.
8. Adverse Effects Profile
- Uterine tachysystole / hyperstimulation (>5 contractions in 10 min), placental uteroplacental hypoperfusion, foetal bradycardia/hypoxia, and uterine rupture
- Acute transient profound hypotension and reflex tachycardia if given as a rapid undiluted IV bolus
- Water intoxication and dilutional hyponatraemia (seizures, coma) when high doses (>20–40 mU/min) are infused in large volumes of electrolyte-free 5% Dextrose due to ADH/V2 receptor cross-reactivity
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Misoprostol / Dinoprostone (Prostaglandins): synergistic uterine hyperstimulation and rupture — wait at least 4–6 hours after vaginal prostaglandin before starting Oxytocin
- Vasopressors (Ephedrine, Phenylephrine): severe postpartum hypertension
- Halogenated volatile anaesthetics (Sevoflurane, Isoflurane): relax the uterus and antagonize Oxytocin
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- COLD-CHAIN MANDATE: Store Oxytocin ampoules strictly in a refrigerator at 2°C–8°C (heat exposure degrades peptide potency and leads to fatal postpartum haemorrhage).
- Always dilute in isotonic electrolyte solutions (0.9% Normal Saline or Ringer's Lactate) rather than 5% Dextrose to prevent hyponatraemic water intoxication.
- Never administer as a rapid IV push during caesarean section.
Storage, Stability & Dispensing Safeguards: STRICT COLD CHAIN: Store in refrigerator at 2°C–8°C; protect from freezing and heat.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2026) • NLEM 2022 (MoHFW) • CDSCO Approved Prescribing Information
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.16]-CMP163 Isoxsuprine Hydrochloride IP — Parenteral Anticonvulsant in Eclampsia, Electrolyte Replenisher &
- [12.17]-C164 Methylergometrine Maleate — High-Alert Obstetric Uterotonics (Neurohypophyseal Peptide, Ergot
- [12.17]-C165 Carboprost Tromethamine — High-Alert Obstetric Uterotonics (Neurohypophyseal Peptide, Ergot
- [12.13] Tranexamic Acid (Antifibrinolytic Haemorrhage Control) — Antifibrinolytic Synthetic Lysine Analogue (Plasminogen Activatio